Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization

Călugăru, Dan; Călugăru, Mihai

doi:10.5301/ejo.5000949

Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization

Abstract

Eur J Ophthalmol 2017; 27(3): e107 - e108

Article Type: CORRESPONDENCE

DOI:10.5301/ejo.5000949

Authors

Dan Călugăru, Mihai Călugăru

Article History

• Accepted on 20/02/2017
• Available online on 07/03/2017
• Published online on 11/05/2017

Disclosures

Financial support: No financial support was received for this submission.

Conflict of interest: None of the authors has conflict of interest with this submission.

This article is available as full text PDF.

If you are a Subscriber, please log in now.
Article price: Eur 36,00
You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
Article added to cart
If you are not a Subscriber you may:
Subscribe to this journal
Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Călugăru, Dan [PubMed] [Google Scholar]
Călugăru, Mihai [PubMed] [Google Scholar] , * Corresponding Author (mihai.calugaru@mail.dntcj.ro)

Affiliations

Department of Ophthalmology, University of Medicine, Cluj-Napoca - Romania

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.